Charles Schwab reports on May 21 against a backdrop that has more to say about insider conviction than short sellers.
The dominant signal heading into the print is the founder's own exit. Charles R. Schwab has sold shares on at least eight separate occasions since late April, offloading roughly 460,000 shares for approximately $42 million in that stretch alone. Net insider sales across all insiders over the past 90 days total more than $59 million. That is not a small programme — it represents a sustained, high-cadence disposal by the firm's namesake at prices clustered near $90-92. Nothing in the data suggests distress, but the pattern is unmistakable: the man who built the company is trimming persistently into strength.
The options market tells a calmer story than the insider tape might suggest. With the put/call ratio at 1.05, options positioning has actually eased well below its recent average of 1.19. It hit a 52-week high of 1.43 back in mid-April; today's reading is closer to the more sanguine end of its one-year range. That April defensive spike has unwound, and traders are not rebuilding hedges ahead of the May 21 report. Availability in the lending market remains ample — borrow is nearly free at 0.31% — and short interest, while up 28% over the past month, stays below 1% of the free float at roughly 0.97%. That is not a structurally short stock.
Analysts are broadly constructive. Four firms — Raymond James, Barclays, TD Cowen, and Piper Sandler — all raised price targets on May 15, the day of the most recent trading session. Barclays lifted to $127 from $117, and Raymond James went to $137, both maintaining positive ratings. The consensus mean target of $116.25 implies roughly 28% upside to the current $90.88 price. Earlier in April, Morgan Stanley trimmed its target twice (first to $135, then to $125) and JPMorgan nudged higher to $131 — net analyst direction over the past month reads as cautiously optimistic. Bulls point to daily average trades running 30% above year-ago levels, pledged asset lending growing 49% year-to-date, and a path to higher net interest income as balance sheet reinvestment continues. Bears focus on the rate sensitivity embedded in that NII recovery: a lower-for-longer rate curve compresses the upside, cash sweep balances remain an open question, and TD Ameritrade integration friction lingers in new net asset flows running below 5%.
The stock is up 2.6% on the week but down 7.6% over the past month, leaving it roughly 27% below the average analyst target — a gap that pricing seems to reflect scepticism about the NII timeline rather than the trading business. Past earnings reactions have been asymmetric to the downside: the April 16 print produced a single-day decline of nearly 8%, followed by a further 11% loss over the subsequent five sessions. The May 21 report will test whether the sequential improvement in client assets and capital ratios is enough to narrow the distance between where the stock trades and where the Street thinks it belongs — and whether the founder's steady exit has already told investors something the numbers have yet to confirm.
See the live data behind this article on ORTEX.
Open SCHW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
